Buparlisib
Non-Small Cell Lunch Cancer
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
55 Active assets in the Non-Small Cell Lunch Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BBB |
Pembrolizumab Shanghai Henlius Biotech | Phase 3 | BB |
Serplulimab Shanghai Henlius Biotech | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BB |
Docetaxel Shanghai Henlius Biotech | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Buparlisib is also rated in:
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →